NeuroSense Completes PARADIGM Study, PrimeC Shows ALS Benefits
Ticker: NRSNW · Form: 6-K · Filed: Dec 4, 2024 · CIK: 1875091
Sentiment: bullish
Topics: clinical-trial-results, drug-development, press-release
TL;DR
NeuroSense's ALS drug PrimeC showed major benefits in PARADIGM study, filing shows.
AI Summary
NeuroSense Therapeutics Ltd. announced on December 4, 2024, the completion of its PARADIGM study. The study highlighted significant efficacy and survival benefits of its drug PrimeC in treating Amyotrophic Lateral Sclerosis (ALS). This announcement was made via a press release filed as an exhibit to their 6-K report.
Why It Matters
The successful completion and positive results of the PARADIGM study could lead to regulatory approval and market availability of PrimeC, offering a new treatment option for ALS patients.
Risk Assessment
Risk Level: medium — While the study results are positive, the actual market impact and regulatory approval are still uncertain, introducing medium risk.
Key Players & Entities
- NeuroSense Therapeutics Ltd. (company) — Registrant
- PrimeC (drug) — Drug studied for ALS
- PARADIGM (study) — Clinical trial name
- Amyotrophic Lateral Sclerosis (ALS) (disease) — Disease being treated
- December 4, 2024 (date) — Date of press release
FAQ
What specific efficacy and survival benefits did PrimeC demonstrate in the PARADIGM study?
The press release, filed as Exhibit 99.1, highlights significant efficacy and survival benefits of PrimeC in ALS, but specific quantitative data is not detailed in this 6-K filing.
When was the press release announcing the completion of the PARADIGM study issued?
The press release was issued on December 4, 2024.
What is the primary purpose of this Form 6-K filing?
This Form 6-K filing is to report the issuance of a press release by NeuroSense Therapeutics Ltd. regarding the completion of its PARADIGM study.
Does NeuroSense Therapeutics Ltd. file annual reports under Form 20-F or Form 40-F?
NeuroSense Therapeutics Ltd. indicated that it files annual reports under Form 20-F.
What is the principal executive office address for NeuroSense Therapeutics Ltd.?
The principal executive offices are located at 11 HaMenofim Street, Building B, Herzliya 4672562, Israel.
Filing Stats: 290 words · 1 min read · ~1 pages · Grade level 11.3 · Accepted 2024-12-04 08:32:44
Filing Documents
- ea0223584-6k_neurosense.htm (6-K) — 12KB
- ea022358401ex99-1_neurosense.htm (EX-99.1) — 17KB
- ex99-1_001.jpg (GRAPHIC) — 3KB
- 0001213900-24-105258.txt ( ) — 34KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. NeuroSense Therapeutics Ltd. Date: December 4, 2024 By: /s/ Alon Ben-Noon Alon Ben-Noon Chief Executive Office 3